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Abstract  45 
 46 
There is increasing interest in the therapeutic utility of vitamin D in asthma, supported by a 47 
significant body of evidence on epidemiological associations between vitamin D insufficiency 48 
and worse asthma control.  In support of a causal relationship, vitamin D beneficially 49 
modulates diverse immunological pathways in heterogeneous asthma endotypes, regulating 50 
the actions of lymphocytes, mast cells, antigen-presenting cells and structural cells to dampen 51 
excessive inflammatory responses.  52 
 53 
Allergic asthma is characterised by a failure of immune tolerance, and development of 54 
pathological responses to inhaled aeroallergens, and vitamin D has been extensively shown to 55 
support immune regulation.  Alarmin cytokines are increasingly implicated in non-allergic 56 
eosinophilic inflammation, which vitamin D also regulates.  Steroid-resistance and pathological 57 
IL-17 responses are features of severe asthma, and vitamin D beneficially enhances the 58 
response to steroids in these individuals.  Additionally, vitamin D enhances anti-microbial 59 
pathways, of relevance to infection-precipitated asthma exacerbations. These mechanisms 60 
support a role for vitamin D as secondary prevention to reduce exacerbations and 61 
inflammation in asthma.  Similar mechanisms, and effects on fetal lung development, likely 62 
underlie a primary prevention therapeutic role in pregnancy for vitamin D to reduce the 63 
development of asthma in children. 64 
 65 
However, randomised controlled trials of variable design show inconsistent positive outcomes 66 
for vitamin D interventions in asthma.  Increased understanding of vitamin D biology reveals 67 
methodological issues that might explain certain negative outcomes.  Importantly, on 68 
systematic review of the trials to-date, vitamin D is beneficial in asthma.  The evidence 69 
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discussed in this review supports the importance of optimising vitamin D in holistic asthma 70 
care.  71 
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Manuscript 72 
 73 
The importance of vitamin D in human health is well established, however, for much of the 20th 74 
century its actions were only considered influential in calcium and phosphate homeostasis.  75 
We have now come to realise that vitamin D has profound paracrine actions throughout the 76 
body and in particular to have major effects on the immune system. 1 2   There is a current 77 
epidemic of vitamin D insufficiency 3 - in humans the most important source for vitamin D 78 
precursors starts with conversion in the skin of 7-dehydrocholesterol to D3 in a reaction 79 
requiring solar ultraviolet B radiation, and reduced exposure to sunlight in our modern 80 
lifestyle is thought responsible for the high prevalence of vitamin D insufficiency. 1 3  As part of 81 
evolving vitamin D research over the last 15 years there has been intense interest in the role 82 
vitamin D may play in airway health and homeostasis, and the effect of vitamin D deficiency on 83 
airways pathology.  In this review we discuss evidence for vitamin D insufficiency / deficiency 84 
contributing to asthma pathology and evidence that vitamin D supplementation should be 85 
considered part of holistic treatment of asthma. 86 
 87 
Epidemiological research has revealed strong, significant associations between diverse aspects 88 
of asthma pathology and reduced levels of serum 25-hydroxyvitamin (25(OH)D) vitamin D, the 89 
major circulating precursor, which is commonly used as a measure of vitamin D status.  Cross-90 
sectional studies have consistently found more severe asthma in patients with lower vitamin D 91 
levels (Table of studies and discussion in Mann et al. 2014 4).  Similar associations seen in other 92 
diseases has led to vigorous discussion about whether these associations are due to causation 93 
or reverse-causation. Three streams of evidence strongly support causation i.e. that reduced 94 
levels of circulating vitamin D can contribute to more severe asthma disease: prospective 95 
epidemiological evidence, mechanistic research and vitamin D supplementation studies.  96 
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Nevertheless reverse-causation (that asthma itself leads to decreased vitamin D levels) is also 97 
likely to be true with reduced time spent outside in more severe asthma and the likelihood that 98 
asthmatic inflammation is vitamin D consumptive, as has been shown for other types of 99 
inflammation. 5  We propose that there is a complex relationship between vitamin D 100 
insufficiency and asthmatic pathology, with a vicious circle of causation and reverse-causation, 101 
leading to progressive worsening of asthma, and that this cycle may be broken by including 102 
vitamin D supplementation in asthma care.  As discussed below this evidence supports a 103 
therapeutic role for vitamin D as secondary prevention in asthmatic patients to reduce asthma 104 
exacerbations and also airway inflammation with remodelling. 105 
 106 
Prospective epidemiological evidence 107 
Most vitamin D epidemiological studies have been cross-sectional, comparing vitamin D levels 108 
to recent asthma control, and therefore more vulnerable to reverse-causation.  Few studies 109 
have compared vitamin D levels to future asthma control.  However, for example, Brehm et al. 110 
(2010) have reported an association between baseline serum vitamin D status and risk of a 111 
severe exacerbation over the following 4 years in children enrolled into the Childhood Asthma 112 
Management Program study. 6  After adjustment for other variables, including physician judged 113 
asthma severity, patients with baseline vitamin D insufficiency (< 30 ng/ml) had higher odds of 114 
an asthma exacerbation requiring hospitalisation or Emergency Department attendance over 115 
the follow-up period. 116 
 117 
Mechanistic Research 118 
Translational research over the last 15 years has shown vitamin D to have a major role in 119 
regulating immunological responses.  Such a role is not surprising given the high frequency of 120 
vitamin D response elements in cells of the immune system such as CD4 T lymphocytes. 7  The 121 
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immunology of asthma is complex and the disease heterogeneous – we are increasingly aware 122 
that multiple independent pathological mechanisms can lead to asthmatic inflammation and 123 
that the relative contribution of the pathways will differ from individual to individual patient.  124 
These pathways interact and subdivisions described below are to aid discussion.  Importantly, 125 
vitamin D has beneficial actions at multiple steps in all these proposed pathways.  126 
Furthermore, chronic uncontrolled asthmatic inflammation leads to airway remodelling - this 127 
is also reduced by vitamin D, likely through its actions on structural cells, as further discussed 128 
below. 129 
 130 
Aero-allergen triggered asthma 131 
Classically asthmatic inflammation was thought primarily due to antigen-dependent immune 132 
responses to aeroallergens, with Th2 lymphocytes, IgE-secreting B lymphocytes and mast cells 133 
featuring prominently in this patho-mechanism (Figure 1).  Naive T lymphocytes become 134 
inappropriately primed to respond to otherwise-innocuous inhaled aeroallergens with Th2 135 
polarity, and upon re-stimulation by inhaled aeroallergens produce the Th2 cytokines IL-4, IL-136 
5 and IL-13 that promote asthma pathology.  IL-4 promotes class-switching of B lymphocytes 137 
to IgE production.  Aero-allergen specific IgE is produced by these B lymphocytes and coats 138 
mast cells.  Then on inhalation of aeroallergens the IgE upon mast cells becomes cross-linked 139 
leading to rapid release of further pro-inflammatory asthma mediators such as leukotrienes 140 
and histamine that cause bronchoconstriction and airway mucus production. 141 
 142 
At the core of this mechanism is a failure of suppression of inappropriate antigen-dependent 143 
immune responses to aeroallergens.  Adaptive immune responses are regulated by diverse 144 
classes of regulatory T lymphocyte (Treg), for example Foxp3 expressing and IL-10 secreting 145 
Tregs, and their coordinated action in healthy individuals ensures tolerance to non-harmful 146 
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antigens.  There is an abundance of evidence that vitamin D plays a vital role in Treg responses. 147 
8  Our laboratory has previously shown in vivo vitamin D status positively correlates with the 148 
frequency of Foxp3+ Tregs 9 and airway levels of IL-10 10 in asthma patients.  In vitro 149 
1,25(OH)2D3 promotes distinct IL-10 and Foxp3 expressing CD4+ T cell populations, which is 150 
influenced by the local cytokine milieu. 9  In addition to Tregs, adaptive immune responses are 151 
also regulated through other mechanisms.  In particular, the quality of antigen presentation 152 
and expression of co-stimulatory signals by dendritic cells (DCs) is important in determining 153 
tolerogenic versus inflammatory immune responses.  Multiple facets of DC activity are 154 
regulated by vitamin D, including antigen presentation and co-stimulatory signals, to promote 155 
tolerogenic DCs. 11 156 
 157 
As well as promoting appropriate antigen tolerance, vitamin D also modulates other aspects of 158 
allergen-stimulated immune responses.  Vitamin D can suppress production of IgE by human B 159 
lymphocytes in vitro and increase IL-10 production, promoting a regulatory B lymphocyte 160 
phenotype. 12 13  Notably, in children vitamin D deficiency is associated with increased levels of 161 
aeroallergen specific IgE. 14 15  Additionally, vitamin D has been shown to have the capacity to 162 
suppress mast cell activation, reducing histamine and TNFα release for example, including in 163 
the context of IgE-dependent activation. 16 17  Vitamin D can also promote mast cell production 164 
of anti-inflammatory IL-10. 18 165 
 166 
In support of these actions of vitamin D being significant, Heine and colleagues have shown in a 167 
ovalbumin-sensitisation model that vitamin D deficient mice have higher levels of ovalbumin-168 
specific IgE. 19  Addition of vitamin D to a desensitisation protocol further reduced airways 169 
concentrations of IL-4 and IL-13 post aerosolised ovalbumin challenge, and also further 170 
reduced airways hyper-responsiveness. 19 171 
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 172 
Epithelial damage and Alarmin cytokine elicited asthmatic inflammation 173 
There is increasing interest in the mechanisms underpinning non-allergic asthma.  Epithelial 174 
damage is now understood to prompt release of cytokines known as Alarmins – e.g. IL-25, IL-175 
33 and TSLP – that directly stimulate multiple cell types including type-2 innate lymphoid cells 176 
(ILC2s) and mast cells. 20   These stimulated ILC2s then produce Th2-type cytokines including 177 
IL-5, which in turn promotes eosinophilic inflammation (Figure 2).  Of these Alarmins, IL-33 178 
appears particularly important in asthma with both its gene (IL33) and the gene for its 179 
receptor (1L1RL1) identified in asthma GWAS studies. 21 180 
 181 
Vitamin D has been shown to modulate the epithelial response to stimulation with a potentially 182 
anti-inflammatory role for this action. 22  However, of specific relevance to asthma is the 183 
capacity of vitamin D to stimulate bronchial epithelial cell production of sST2, a soluble decoy 184 
blocker for IL-33, and for this epithelial-produced sST2 to decrease the pro-inflammatory 185 
effect of IL-33 on target cells such as mast cells. 23 186 
 187 
There is relatively little evidence as to the effect of vitamin D on ILC2s and eosinophils.  Ethier  188 
et al. have shown vitamin D to be able to enhance eosinophil viability with reduced production 189 
of pro-inflammatory necrotic granules. 24  Ruiter and colleagues have shown vitamin D to 190 
reduce pro-inflammatory cytokine production by stimulated ILC2s. 25 191 
 192 
Viral infections in particular trigger epithelial IL-33 release, 26 which is important given that 193 
Th2-biased asthmatic pathology has been shown to impair appropriate anti-viral immune 194 
responses. 27  Indeed asthma exacerbations are frequently associated with viral respiratory 195 
tract infections.  Vitamin D, however, enhances antimicrobial immune responses through many 196 
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mechanisms.  It enhances cellular production of antimicrobial peptides (such as cathelicidin) 197 
and autophagy, important in the response to both bacterial and viral infections. 28 29 30  198 
Consistent with these actions of vitamin D, meta-analysis has shown vitamin D 199 
supplementation of appropriate patients to reduce acute respiratory tract infections. 31 200 
 201 
Steroid-resistant asthma and IL-17 202 
In a proportion of patients with the most severe asthma the pathology appears to have some 203 
distinct features, in particular corticosteroid-resistance and an apparent pathological role for 204 
IL-17.  Multiple pathways to steroid-resistance in airways disease have been described. 32  205 
Airway colonisation with pro-inflammatory bacteria such as Haemophilus influenza, oxidative 206 
stress (for example from air pollution) and vitamin D deficiency itself are major contenders for 207 
causing acquired steroid-resistance in asthma.  Vitamin D enhances anti-microbial pathways 208 
and vitamin D also promotes anti-oxidant responses. 33  Additionally vitamin D ameliorates 209 
steroid-resistant inflammation through its direct actions on lymphocytes (as discussed below) 210 
and monocytes. 34   Steroid-insensitive asthmatics have impaired steroid-induced production 211 
of anti-inflammatory IL-10.  In vitro vitamin D enhances steroid-induced lymphocyte 212 
production of IL-10 and supplementation of steroid-resistant asthmatic patients with the 213 
calcitriol form of vitamin D restores both the clinical and immunological IL-10 response to 214 
corticosteroids. 35 36 37  Furthermore, we have shown that corticosteroids actually promote in 215 
steroid-resistant individuals production of IL-17, thought in this context to cause pathological 216 
neutrophilic inflammation, with amelioration after vitamin D supplementation. 37  217 
Subramanian and colleagues have recently reported vitamin D to reduce production of pro-218 
inflammatory cytokines by stimulated neutrophils. 38   However vitamin D did enhance the 219 
anti-bacterial activity of neutrophils, via enhanced production of antimicrobial peptides rather 220 
than increased production of elastase or reactive oxygen species. 38  These findings are 221 
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consistent with earlier findings of vitamin D responsiveness of neutrophils reported by 222 
Takahashi and colleagues. 39 223 
 224 
Vitamin D and airway remodelling 225 
The downstream effect of asthmatic immune responses, regardless of the mechanisms 226 
precipitating those responses, is airway narrowing.  Over the short-term this is due to smooth 227 
muscle constriction and mucus secretion, whilst over the longer-term airway remodelling and 228 
fibrosis occur.  Importantly, vitamin D has actions on airway smooth muscle including 229 
inhibiting airway smooth muscle cell proliferation. 40 41  Consistent with this Gupta and 230 
colleagues have previously shown airway smooth muscle volume fraction in endobronchial 231 
biopsies to negatively correlate with serum vitamin D concentrations in steroid-refractory 232 
severe paediatric patients with asthma. 14 233 
 234 
Randomised controlled trials (RCTs) of vitamin D to treat asthma 235 
Over the last few years several randomised controlled clinical trials of vitamin D therapies to 236 
improve asthma control have completed and published their findings.  These studies of vitamin 237 
D as secondary prevention to reduce asthma exacerbations have reported a mixture of positive 238 
and negative results in their primary outcome measures with, nevertheless, multiple positive 239 
secondary outcome measures in some trials with negative primary outcomes.  For example, the 240 
VIDA trial (Castro et al.), despite a negative primary outcome of time to first exacerbation, 241 
found in a responder analysis that for each 10ng/ml increase in serum 25(OH)D there was a 242 
significant reduction in the rate of treatment failures and of exacerbations. 42  Furthermore, in 243 
a recent Cochrane Review of vitamin D for secondary prevention to reduce exacerbations in 244 
asthmatic patients, meta-analysis shows vitamin D supplementation to significantly reduce the 245 
rate of severe exacerbations in asthmatic patients. 43 246 
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 247 
One possible explanation for the divergent results is under-powering in some studies and 248 
smaller effect sizes than anticipated.  However, we believe that differences and limitations in 249 
study design partly explain the differences in study outcome (see Table 1). These 250 
methodological issues in vitamin D treatment trials are not specific to asthma and are worthy 251 
of detailed discussion.   252 
  253 
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Table 1: Summary of major vitamin D secondary prevention RCTs in asthma 254 
ACT; Asthma Control Test. ATAQ; Asthma Therapy Assessment Questionnaire. FEV1; Forced 255 
Expiratory Volume in 1 second. 256 
 257 
Trial 
Study Design: Population & Intervention Primary (1ry) and major Secondary (2ndry) Outcomes 
Majak et al. 2011 44 
Population: 48 children (5-18 years old) with 
newly diagnosed asthma. 
Intervention: 500 IU D3 daily (versus 
placebo).  In addition to inhaled steroid. 
Outcomes: Significantly lower percentage of participants 
experiencing an asthma exacerbation in the D3 treated 
group.  No significant difference in improvements in ATAQ 
score and FEV1 between the two groups. 
Lewis et al. 2012 45 
Population: 30 children (6-17 years age) with 
asthma; 97% with serum 25(OH)D < 30 ng/ml.  
20 completed study (33% drop-out in both 
groups). 
Intervention: 1000 IU D3 daily (versus 
placebo). 
Outcomes: No significant effect of D3 therapy on either 
ACT score or FEV1. 
Yadav et al. 2013 46 
Population: 100 children (5-13 years old) with 
moderate to severe asthma. 
Intervention: 60 000 IU D3 per month or 
placebo. 
1ry Outcome: Significantly greater improvement in 
severity of asthma according to GINA guidelines at 6 
months in D3 treated group. 
 
2ndry Outcome: Significantly fewer exacerbations in the 
D3 treated group. 
Castro et al. 2014 (VIDA Study) 42 
Population: 408 adult asthmatics all with 
serum 25(OH)D < 30 ng/ml. 
Intervention: Placebo versus 100 000 IU D3 
bolus dose followed by 4000 IU daily. 
1ry Outcome: No significant effect on rate of first asthma 
treatment failure. 
2ndry Outcomes: No significant effect on rate of first 
asthma exacerbation.  Significantly greater taper of inhaled 
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Tapering inhaled steroids dependent on 
asthma control in both groups.  
steroids in the D3 treated group. 
In a vitamin D3 responder analysis: Rate of first 
exacerbation and overall exacerbation rate were both 
significantly lower in the D3 incremented subgroup.  
Martineau et al. 2015 (ViDiAs Study) 47 
Population: 250 adult asthmatics; 82% with 
serum 25(OH)D < 75 nmol/l and 58% with 
serum 25(OH)D < 50 nmol/l. 
Intervention: 120 000 IU D3 every two months 
(versus placebo). 
1ry Outcome: No significant effect of D3 treatment on time 
to first severe asthma exacerbation or time to first upper 
respiratory infection. No effect modification of baseline 
vitamin D status on either co-primary outcome. 
 
Tachimoto et al. 2016 48 
Population: 89 schoolchildren (6-15 years age) 
with asthma.  Median average serum 25(OH)D 
29 ng/ml. 
Intervention: 800 IU D3 /day or placebo. 
1ry Outcome: Significantly better changes in asthma 
control levels as defined by GINA in D3 treated arm. 
  258 
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 259 
The first issue is whether vitamin D supplementation is beneficial in all patients or only 260 
beneficial where it corrects low vitamin D levels in deficient patients.  Unlike in trials of 261 
pharmacologic drugs, in trials of vitamins patients at baseline have variable circulating levels 262 
of the vitamins and will have variable natural intake over the course of the trial through their 263 
normal activities of daily living.  Subgroup analyses in two studies of vitamin D as a treatment 264 
for COPD have shown significant benefit from vitamin D supplementation in the subgroups of 265 
patients with marked vitamin D insufficiency (serum 25(OH)D levels < 10ng/ml and < 50 266 
nmol/l  respectively for the two studies). 49 50  Similarly Martineau and colleagues have 267 
reported a significant interaction between baseline vitamin D status and benefit of 268 
supplementation in reducing acute respiratory tract infections, with greatest benefit in those 269 
with serum 25(OH)D < 25 nmol/l. 31  A major limitation of some studies may therefore be that 270 
many participants were relatively vitamin D sufficient at baseline and less likely to benefit. 271 
Not all supplemented patients in the treatment arms of these trials actually achieved vitamin D 272 
sufficiency during the trials.  However, that supplementation does achieve vitamin D 273 
sufficiency appears an important determinant of benefit.  In the VIDA trial approximately one 274 
fifth of participants in the vitamin D3 treatment arm did not achieve a serum 25(OH)D3 >= 30 275 
ng/ml (equivalent to approximately 75 nmol/l).  Although the rate of exacerbations was not 276 
significantly decreased in the overall treatment group compared to placebo, in an exploratory 277 
responder analysis when those not achieving a 25(OH)D3 >= 30 ng/ml in the treatment arm 278 
were excluded then there was a significant reduction in exacerbations in the treatment arm 279 
compared to placebo. 42 280 
Furthermore, the optimum vitamin D level in asthma is unclear.  A serum 25(OH)D3 target 281 
concentration of 75 nmol/l (30ng/ml) is often quoted but this is based on inferences from the 282 
actions of vitamin D in calcium-phosphate homeostasis. 51  The responder analysis from the 283 
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VIDA trial is consistent with this target, 42 however, that does not mean that this is necessarily 284 
the optimum target vitamin D level in asthma or for general health.  There are both proponents 285 
of lower target vitamin D concentrations and high target serum levels (such as 100nmol/l 286 
40ng/ml). 51 52  In support of the latter are the higher physiological ranges of vitamin D seen in 287 
some populations and emerging evidence from vitamin D trials in other medical fields. 53 288 
However, although in clinical practice we assay serum 25(OH)D concentrations as a measure of 289 
patient vitamin D status, whether this is the most appropriate form to measure is uncertain.  290 
Vitamin D has a complicated metabolic pathway and it is possible that levels of a precursor or 291 
other metabolite are more important. 54  Additionally different actions of vitamin D may 292 
require different threshold concentrations of serum vitamin D.  Finally, the bioavailability of 293 
circulating vitamin D metabolites is dependent on other factors such as circulating vitamin D 294 
binding protein (VDBP), and polymorphisms in VDBP and other vitamin D axis genes may 295 
affect the supplementation dose necessary to achieve functional vitamin D sufficiency. 55 296 
 297 
Secondly, the correct form of vitamin D to give as a supplement and correct dosing strategy is 298 
uncertain (reviewed in detail by Hollis and Wagner, 2013 54 ).  In particular, bolus vitamin D 299 
supplementation (as used in some asthma studies) may be immunologically problematic, 300 
causing large swings in serum levels and inducible homeostatic enzymes, with dysregulation of 301 
other vitamin D regulated pathways. 56  Indeed a recent meta-analysis of trials of vitamin D to 302 
prevent acute respiratory tract infections found regimens with regular vitamin D dosing to be 303 
associated with a protective action of vitamin D but regimens with high-dose boluses to not 304 
show protective effect. 31  The commonest forms of vitamin D to give as supplementation are 305 
ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) – although there is little research 306 
in to ergocalciferol supplementation in asthma by extrapolating from other diseases 307 
cholecalciferol is more likely to be beneficial than ergocalciferol. 57  Finally, correction of 308 
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vitamin D insufficiency through increased exposure to ultraviolet radiation may be more 309 
physiological and more effective in asthma than oral supplementation. 58 310 
 311 
Thirdly, vitamin D supplementation may be more beneficial in paediatric asthma 44 48 than in 312 
adult asthma. 42 47  Notably although Sharief and colleagues found significant associations 313 
between serum 25(OH)D and IgE sensitisation to multiple allergens in children and 314 
adolescents, significant associations were much fewer in adults. 15  The recent Cochrane 315 
Review of vitamin D as secondary prevention in asthma did not directly address this question, 316 
however the recent closely-related systematic review of vitamin D to prevent acute respiratory 317 
tract infections did not find a significant interaction between age and benefit of vitamin D. 31  A 318 
paediatric versus adult difference in benefit of vitamin D could relate to immunopathological 319 
differences in childhood onset, typically atopic asthma, and adult asthma. Different 320 
immunological pathways are likely to be of prime importance in childhood-onset asthma 321 
compared to adult-onset asthma, and vitamin D may have less effect on the pathways of prime 322 
importance in adult-onset asthma.  Alternatively, differences in the capacity of vitamin D to 323 
regulate immune responses in children and adults may perhaps reflect establishment of 324 
epigenetic responses to chronic vitamin D insufficiency in adults after years of vitamin D 325 
deficiency, leading to these individuals having less capacity to respond to vitamin D 326 
therapies.59  327 
 328 
Fourthly whilst the above mechanistic studies show the capacity of vitamin D to beneficially 329 
modulate the different pathways thought to underlie different asthma endotypes, it is possible 330 
that some of these actions of vitamin D have little clinical efficacy.  Therefore vitamin D 331 
therapies may be particularly beneficial in discrete endotypes of asthma.  The larger RCTs have 332 
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not selected for specific asthma endotypes, however, we have shown evidence for a particular 333 
role for vitamin D therapy in a severe steroid-resistant asthma endotype. 36 37 334 
 335 
Further large studies of daily vitamin D supplementation to improve asthma control in vitamin 336 
D deficient asthmatic children and adults are needed to better understand these issues.  337 
Nevertheless, there is increasing realisation that vitamin D deficiency negatively impacts on 338 
general health status and that vitamin D supplementation rarely has side-effects.  Therefore, 339 
optimising vitamin D status is increasingly becoming part of standard holistic clinical care in 340 
asthma (see Box 1 for Clinical Recommendations). 341 
 342 
Box 1: Clinical Recommendations 343 
 344 
CLINICAL RECOMMENDATIONS 345 
- Daily supplementation of vitamin D deficient and insufficient patients is safe and 346 
has positive benefit to health in asthma and other diseases, but infrequent high-347 
dose bolus supplementation should be avoided. 348 
- Supplementation should be given as Vitamin D3 (cholecalciferol). 349 
- The exact serum 25(OH)D concentration below which supplementation should be 350 
started and best dosing regimens remain to be established.  We would suggest 351 
supplementing those with serum 25(OH)D < 50 nmol/l and starting with a dose of 352 
1000 – 4000 IU/day depending on baseline concentration.  Serum vitamin D 353 
should be reviewed after a few months of supplementation and if vitamin D 354 
sufficiency has not been achieved then the supplementation dose should be 355 
increased in order to achieve vitamin D sufficiency. 356 
- Serum vitamin D concentrations should be checked in women planning 357 
pregnancy pre-conception and also in all pregnant women, with daily high-dose 358 
supplementation given during pregnancy.  In those planning pregnancy sufficient 359 
vitamin D supplementation should be given to rapidly achieve vitamin D 360 
sufficiency. 361 
 362 
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 363 
 364 
Early life vitamin D and primary prevention of asthma 365 
Vitamin D deficiency and insufficiency is extremely common in pregnancy, and is associated 366 
with preeclampsia, gestational diabetes mellitus and other co-morbidities of pregnancy. 60  It 367 
has also been associated with increased respiratory infections, and asthma in the newborn and 368 
children in many studies. 61 Vitamin D is proposed to beneficially impact fetal and 369 
neonatal lung maturation, as well as immunity in a manner likely to promote maternal-fetal 370 
tolerance, and to protect mother and fetus from infection. 61 62  Importantly these associations 371 
between maternal vitamin D insufficiency and asthma in the offspring cannot be explained as 372 
due to reverse causation although an effect of unmeasured confounding variables in these 373 
studies is possible. 374 
The mechanisms by which early life vitamin D could help reduce development of asthma 375 
include (i) its capacity to support development of tolerogenic immune responses (as discussed 376 
above), (ii) facilitating appropriate antiviral and antibacterial immune responses, (iii) 377 
enhancing barrier properties of the epidermis and decreasing eczema, and (iv) enhancing 378 
appropriate lung development – all factors important in determining whether an individual 379 
develops symptomatic chronic airway disease. 63  In particular in utero vitamin D has been 380 
shown to affect expression of genes important in early pulmonary development (for example 381 
branching morphogenesis) and to influence multiple aspects of later lung development 382 
including alveolar development and surfactant secretion. 62  64  These vitamin D regulated 383 
developmental processes occur at different times in gestation suggesting multiple vital 384 
windows for vitamin D actions at different stages of gestation.  Furthermore, as vitamin D 385 
research continues an increasing number of asthma-relevant development processes are being 386 
revealed to be influenced by vitamin D, for example recent evidence for a likely influence of in 387 
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utero vitamin D status on the early-life microbiome. 65 388 
These data, with mechanistic evidence discussed above, has now led to randomised controlled 389 
trials of high-dose vitamin D supplementation as primary prevention to avert the development 390 
of recurrent wheeze and asthma in offspring. 391 
Two large RCT, using doses of vitamin D known to significantly increase vitamin D status of 392 
pregnant women, 61 have recently reported similar and encouraging effects on infant 393 
respiratory outcomes.  In the COPSAC study, Chawes et al., supplemented pregnant women 394 
with 2800 IU/d vitamin D3 in the third trimester of pregnancy, and reported a reduction in 395 
episodes of troublesome lung symptoms in the offspring through 3-years though no significant 396 
effect on risk of persistent wheeze. 66  In the VDAART trial, Litonjua et al., supplemented with 397 
4400 IU/d vitamin D3 during the second and third trimester, reporting a significant reduction 398 
in allergic sensitizations and a trend for a reduction in recurrent wheeze and asthma in 399 
offspring through 3-years. 67  Importantly, no increase in adverse effects were reported in 400 
these or other comparable pregnancy studies. 60 66 67   401 
In an ancillary study of cord blood samples from a subset of babies born to women within the 402 
VDAART cohort, Hornsby and colleagues show supplementation to significantly enhance pro-403 
inflammatory cytokine responses to mitogen and TLR-agonist stimulation, increase TLR2 and 404 
TLR9 gene expression, and IL-17A secretion in response to T cell receptor-ligation. 68  Thus, 405 
vitamin D supplementation during pregnancy modifies the immune system of the neonate in a 406 
manner that is predicted to protect the host against pathogenic infections and reduce 407 
development of asthma. 408 
However, similar methodological issues exist with primary prevention trials of vitamin D to 409 
those discussed above with respect to secondary prevention trials.  Stratification of response 410 
by baseline vitamin D status is evident - in secondary analyses of the VDAART study infants 411 
born to high-dose supplemented mothers who had circulating levels of vitamin D of 30ng/ml 412 
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or higher at recruitment (sufficiency range) demonstrated a striking and significant reduction 413 
in recurrent wheeze and asthma through 3-years.  However, infants of high-dose 414 
supplemented mothers who were vitamin D deficient at baseline (10-18 weeks gestation) did 415 
not have the same significant benefit from randomisation to high-dose vitamin D.  This 416 
indicates the likelihood of important effects of vitamin D throughout neonatal development, 417 
likely to include bone, pulmonary and immune effects (as discussed above), and including 418 
during the first trimester. 69  It may also suggest that maternal vitamin D deficiency leads to 419 
epigenetic changes in the offspring resulting in relative vitamin D resistance. 59  Therefore 420 
achieving vitamin D sufficiency needs to be a clinical priority pre-conception.  High-dose 421 
supplementation in both these trials did not include what appears to be a critical window for 422 
vitamin D actions in early pregnancy / pre-conception.  Notably this influence of baseline 423 
vitamin D status on clinical benefit of vitamin D supplementation to prevent development of 424 
asthma is opposite to that noted in the secondary prevention RCTs discussed above. 425 
Secondly, similar to the secondary prevention trials, not all patients in these primary 426 
prevention trials achieved vitamin D sufficiency despite high-dose supplementation (75% in 427 
the VDAART trial and 81% in the COPSAC trial). 67 66  This underscores the likelihood that 428 
different individuals require different doses of vitamin D to achieve sufficiency, however, both 429 
trials did note a significant proportion of participants not to have been adequately adherent to 430 
the vitamin D intervention.  Previously infrequent bolus dosing of vitamin D supplements has 431 
been suggested as a strategy to improve adherence but as we discuss above such infrequent 432 
bolus dosing may be immunologically problematic. 433 
It is also too early to determine whether high-dose vitamin D supplementation in these 434 
primary prevention studies has successfully reduced the proportion of children going on to 435 
develop asthma – reported follow-up to date is for up to age 3 whereas asthma is often 436 
diagnosed slightly later in childhood.  Long-term follow-up of these patients is eagerly awaited. 437 
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The longitudinal effects of vitamin D during the first 10 years of life were investigated in a 438 
high-risk Australian cohort in order to determine relationships between 25(OH)D levels and 439 
susceptibility to allergic sensitization, respiratory tract infections, and asthma. 70  The study 440 
showed that 25(OH)D deficiency in early childhood is associated with increased risk for 441 
persistent asthma.  The authors proposed that vitamin D may act by influencing susceptibility 442 
to early allergic sensitization, and/or upper respiratory tract colonization with bacterial 443 
pathogens, or both.  444 
Together these very recent studies bring real enthusiasm to investigate strategies that restore 445 
vitamin D sufficiency in pregnancy and the first years of life, which offer the potential to reduce 446 
both important asthma risk factors, namely allergic sensitizations and respiratory tract 447 
infections, as well as asthma itself.  A future challenge will be to determine safe and effective 448 
regimens of vitamin D3 supplementation in the newborn and infant. 449 
 450 
Conclusions 451 
 452 
There is a wealth of epidemiological evidence of a detrimental association between vitamin D 453 
insufficiency and asthma, and translational studies have shown vitamin D to have the capacity 454 
to beneficially regulate diverse aspects of asthma pathology.  Methodological considerations 455 
with vitamin D randomised controlled trials to-date may underlie less impressive than hoped 456 
clinical effects in the trials.  Further clinical trials, with revised protocols learning from the 457 
issues discussed above, are needed.  Nevertheless, the evidence-base increasingly supports 458 
vitamin D supplementation being a safe, practical and beneficial part of the comprehensive 459 
management of asthma. 460 
  461 
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Figure Legends 462 
 463 
Figure 1: Illustrative schematic of the mechanistic pathway of aero-allergen stimulated 464 
asthmatic inflammation, and steps at which vitamin D acts. 465 
Vitamin D can act beneficially at multiple steps along the pathway to prevent / reduce 466 
asthmatic inflammation. 467 
  468 
Figure 2: Schematic for non-allergic eosinophilic asthmatic inflammation.   469 
Epithelial injury, for instance from proteases or viral infection, stimulates epithelial release of 470 
Alarmin cytokines such as IL-25 and IL-33.  These cytokines act on immune cells such as ILC2s 471 
and mast cells to elicit production of Th2-type cytokines that stimulate eosinophilic 472 
inflammation.  Vitamin D can inhibit this pathway at multiple steps. 473 
 474 
Figure 3: Diverse stimuli can elicit steroid-resistant asthmatic inflammation 475 
Th17-mediated neutrophilic airways inflammation can follow diverse precipitants such as 476 
oxidative stress that are sensitive to modulation by vitamin D.  Furthermore, Th17 477 
lymphocytes and neutrophils themselves are also beneficially sensitive to vitamin D. 478 
 479 
 480 
 481 
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